Simon J. Hall is an American researcher who is the Associate Professor and Kyung Hyun Kim, M.D. Chair of Urology and Assistant Professor, Department of Gene and Cell Medicine at The
Mount Sinai School of Medicine, as well as the Director of the Barbara and Maurice Deane Prostate Health and Research Center at The
Mount Sinai Medical Center, both in
New York City.[1][2]
Hall is the author of four book chapters and more than 30 peer-reviewed articles. He has received fourteen grants and was listed among New York Magazine’s Best Doctors in 2007, 2008 and 2009.[3][4]
From 1997 until 2001 Hall was the director of the Department of Urology at
Elmhurst Hospital in
Queens. In 2001, he was named director of the Barbara and Maurice Deane Prostate Health and Research Center at The Mount Sinai Medical Center, and in 2003 he was named Chair of Mount Sinai's Department of Urology. In 2009, he was named the Kyung Hyun Kim, M.D. Chair in Urology.
2001: Dr. Solomon Silver Award in Clinical Medicine, Mount Sinai School of Medicine
Clinical trials
Autologous PAP-loaded dendritic cell vaccine (APC8015, Provenge) in patients with non-metastatic prostate cancer who experience PSA failure after radical prostatectomy. Sponsor:
Denedron Corp, GCO#01-0592.[5]
Autologous PAP-loaded dendritic cell vaccine (APC8015, Provenge) in patients with hormone refractory disease. Sponsor: Dendreon Corp.[6]
A Randomized, Multicenter, Single Blind Study in Men with Metastatic Androgen Independent Prostate Cancer to Evaluate
Sipuleucel-T Manufactured with Different Concentrations of PA2024 Antigen (P07-2) Sponsor: Dendreon Corp, GCO #08-0813.[7]
Book chapters
Partial list:
Thompson, TC, Timme, TL, Hall, SJ, and Stapleton, AMF. Perspectives on the Molecular Biology of Prostate Cancer, In Vogelzang, NJ, Scardino, PT, Shipley, WU, and Coffey, DS. (Eds.) Comprehensive Textbook of Genitourinary Oncology, Williams & Wilkins, Baltimore, MD, 1996.
ISBN0-7817-4984-0.[8]
Hall SJ, Kresina TF, Trauger R, and. Conley BA. Gene Therapy for the Treatment of Cancer, In Kresina TF (Ed.), An Introduction to Molecular Medicine and Gene Therapy, John Wiley & Sons, New York, NY. 2001.
ISBN978-0-471-39188-3.[9]
Millikan RE and Hall SJ. New Possibilities in Systemic Treatment for Metastatic Bladder Cancer, In Droller MJ (Ed.), Bladder Cancer: Current Diagnosis and Treatment, Humana Press, Totowa, NJ. p. 393-422, 2001.
ISBN0-89603-818-1.[10]
Publications
Partial list:
Stock, RG; Cesaretti, JA; Hall, SJ; Stone, NN (December 2009). "Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy". BJU Int. 104 (11): 1631–6.
doi:
10.1111/j.1464-410X.2009.08661.x.
PMID19493260.
S2CID28804721.
Ip, C; Hall, SJ (June 2007). "Hormonal implications in the development and treatment of prostate cancer". Endocrinol. Metab. Clin. North Am. 36 (2): 421–34.
doi:
10.1016/j.ecl.2007.03.009.
PMID17543727.
^Hall, Simon J.; Thompson, Timothy C. (1997). "Spontaneous but not experimental metastatic activities differentiate primary tumor-derived vs metastasis-derived mouse prostate cancer cell lines". Clinical & Experimental Metastasis. 15 (6): 630–638.
doi:
10.1023/A:1018499515883.
PMID9344047.
S2CID1912375.
^Kresina, Thomas F. (2000). Kresina, Thomas F (ed.). Wiley InterScience: An Introduction to Molecular Medicine and Gene Therapy.
doi:
10.1002/0471223875.
ISBN978-0471391883.